Levin Capital Strategies’s Denali Therapeutics DNLI Stock Holding History

Levin Capital Strategies’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-13,000	Closed	-$279K	–	249
2023 Q4	$279K	Sell	13,000 -7,000	-35%	-$139K	0.03%	194
2023 Q3	$413K	Buy	+20,000	New	+$507K	0.05%	149
2022 Q3	–	Sell	-5,000	Closed	-$147K	–	256
2022 Q2	$147K	Buy	+5,000	New	+$131K	0.02%	216

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Levin Capital Strategies's DNLI Position: Q1 2024 in Review

Levin Capital Strategies sold out of Denali Therapeutics (DNLI) in Q1 2024, closing a stake of 24,000 shares — an estimated $515K sold.

Levin Capital Strategies first reported a position in DNLI in Q2 2022 and held it in 5 quarters. The position peaked at $515K in Q4 2023. 210 funds tracked by Wall St. Rank hold DNLI as of Q1 2024.

Levin Capital Strategies reported no remaining Denali Therapeutics position as of Q1 2024 after selling out during the quarter.
Levin Capital Strategies sold 24,000 Denali Therapeutics shares in Q1 2024, an estimated $515K.
Levin Capital Strategies first reported a position in Denali Therapeutics in Q2 2022 and held it in 5 quarters.
Levin Capital Strategies's Denali Therapeutics position peaked at $515K in Q4 2023.
210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2024.

Based on Levin Capital Strategies's 13F filing for Q1 2024, filed 16 May 2024.